165 related articles for article (PubMed ID: 23821328)
1. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.
Nam EJ; Lee M; Yim GW; Kim JH; Kim S; Kim SW; Kim JW; Kim YT
Oncologist; 2013; 18(7):843-9. PubMed ID: 23821328
[TBL] [Abstract][Full Text] [Related]
2. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B
Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
5. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.
Dueñas-Gonzalez A; López-Graniel C; González-Enciso A; Cetina L; Rivera L; Mariscal I; Montalvo G; Gómez E; de la Garza J; Chanona G; Mohar A
Ann Oncol; 2003 Aug; 14(8):1278-84. PubMed ID: 12881393
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
Umayahara K; Takekuma M; Hirashima Y; Noda SE; Ohno T; Miyagi E; Hirahara F; Hirata E; Kondo E; Tabata T; Nagai Y; Aoki Y; Wakatsuki M; Takeuchi M; Toita T; Takeshima N; Takizawa K
Gynecol Oncol; 2016 Feb; 140(2):253-8. PubMed ID: 26701414
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
11. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
Tharavichitkul E; Lorvidhaya V; Kamnerdsupaphon P; Sukthomya V; Chakrabandhu S; Klunklin P; Onchan W; Supawongwattana B; Pukanhaphan N; Galalae R; Chitapanarux I
BMC Cancer; 2016 Jul; 16():501. PubMed ID: 27435245
[TBL] [Abstract][Full Text] [Related]
12. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
14. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
Takekida S; Fujiwara K; Nagao S; Yamaguchi S; Yoshida N; Kitada F; Kigawa J; Terakawa N; Nishimura R
Int J Gynecol Cancer; 2010 Dec; 20(9):1563-8. PubMed ID: 21370599
[TBL] [Abstract][Full Text] [Related]
16. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
Ryu SY; Lee WM; Kim K; Park SI; Kim BJ; Kim MH; Choi SC; Cho CK; Nam BH; Lee ED
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e577-81. PubMed ID: 21840137
[TBL] [Abstract][Full Text] [Related]
18. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
[TBL] [Abstract][Full Text] [Related]
19. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Joerger M; von Pawel J; Kraff S; Fischer JR; Eberhardt W; Gauler TC; Mueller L; Reinmuth N; Reck M; Kimmich M; Mayer F; Kopp HG; Behringer DM; Ko YD; Hilger RA; Roessler M; Kloft C; Henrich A; Moritz B; Miller MC; Salamone SJ; Jaehde U
Ann Oncol; 2016 Oct; 27(10):1895-902. PubMed ID: 27502710
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
Kim YS; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
Gynecol Oncol; 2008 Jan; 108(1):195-200. PubMed ID: 17963825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]